that reacts equally well with fragment D and fibrinogen. This solid-phase assay is shown to be specific and about 10-fold more sensitive than a standard liquid-phase competition radioimmunoassay in which the same antibody was used. (6) . Fibrinogen and one of its degradation products, fragment D (FgD), may be involved in hematopoiesis as well (7) . A sensitive, simple assay for FgD concentration might prove useful for monitoring these phenomena. Radioimmunoassays (RIA) for FgD and fragment E of human Fg (8, 9) have been developed in which Fg-absorbed rabbit antisera are used. The difficulties in obtaining large lots of standard reagents and separation of liquid phase immune complexes from free antigen have prompted us to develop a solid-phase RIA that involves monoclonal antibodies (MoAb). The relative advantages of monoclonal and polyclonal antibodies for clinical assays are the subject of a recent review (10) .
Several MoAb to Fg and FgD have been reported (11, 12) . Most of these do not discriminate between the two molecules (12) or show only preferential, not absolute, specificity for (14) as described above. Each preparation was examined for purity by two-dimensional gel electrophoresis (17) and equilibrium constants The bead fragments were washed in BSA/PBS, diluted 50-fold in BSAJPBS, and 50 ML was apportioned into 10 x 75 mm glass tubes with an Eppendorf micropipettor.
We took care to keep the beads suspended during pipetting, and pipette tips were cut off about 5 mm from the end, to allow easy passage of beads. Samples (50 ML) of Fg or FgD (2 mg to 20 ng/mL) diluted in BSAJPBS containing 20 mmol of e-aminocaproic acid (Aldrich Chemical Co., Milwaukee, WI 53233) per liter were added to the beads and allowed to incubate at 4 #{176}C on a Titertek vibrator (setting = 2) for 3 h. because no FgD was detected in subsequent RIA of serum samples diluted 10-fold in PBS. After the beads were inQubated with test samples, 2 mL of BSAtPBS with #{128}-aminocaproic acid was added to each tube and the beads were centrifuged (1000 x g, 5 mm). The supernate was aspirated and discarded and the beads were washed two more times before we added 50 ML of '251-labeled 280-4A IgG (1 g/mL at 22 200 cpmlng) in BSAIPBS containing normal mouse serum diluted 20 fold and 0.5 g of the nonionic detergent NP4O (Particle Data Laboratories Ltd., Elmhurst, IL 60126) per liter. After incubation at 4 #{176}C for an additional 3 h on the vibrator, beads were washed twice, and their radioactivity was then measured in a gamma counter.
The values (counts/mm) for radioactivity bound to beads were normalized to the maximum amount of the '25I-labeled 280-4A preparation that bound to beads covalently coupled with 1.0 mg of FgD per milliliter.
Results

Monoclonal Antibody
We made numerous attempts to isolate a high-affinity MoAb specific for FgD. Several high-affinity antibodies cross reactive for Pg and FgD were identified (11, 14) , but all antibodies that bound preferentially This could be the result of either nonspecific binding of Fg to the beads or Fg degradation resulting in FgD production during the assay.
DIscussion
The usefulness of immunoassays for clinical application is regulated by their specificity and sensitivity. For these two considerations, as well as for a reproducible source of reagents, it is desirable to use MoAb (10). We have developed a number of MoAb for use in assay of FgD. Most of these react either with Pg and FgD equally or with FgD preferentially (11), but MoAb 231-12B has a very restricted if not absolutely specific reaction with FgD. For example, using this MoAb in competition liquid-phase RIA (Figure 2 ), 100 no competition was detected with 100 g of Pg per 50 ML, while significant competition (20%) was obtained with 500 ng of FgD per 50 ML. To the limits of these tests, MoAb 231-12B reacts at least 200-fold better with FgD than with Fg. Wellcome Reagents, Ltd.). Our two-site, solid-phase RIA gives increased sensitivity of detection of FgD relative to the liquid-phase RIA. We have shown that it is possible to "drive" the specific reaction between MoAb 231-12B and FgD with large amounts of antibody (10 Mg), so that a large fraction of the FgD is bound, even in a low-concentration solution. The FgD specifically bound to the solid-phase matrix via MoAb 231-12B, is detected with a radiolabeled, high-affinity antibody (280-4A), which is equally reactive with Pg and FgD. The data in Figures 2 and 3 show that, in practice, this type of assay is about 10-fold more sensitive than its liquid-phase counterpart.
Double-MoAb assays have been reported that enhance specificity by using two partly specific MoAb (20, 21) , but the present report is the first to show that a solidphase, double-MoAb RIA can result in increased sensitivity of detection.
There is some nonspecific binding of Pg to the MoAb beads, but the assay discriminates between Pg and PgD by at least 100-fold. Nonspecific binding plagues many of the assay systems used to discriminate between these molecules (22). We also observed that binding of the detection antibody (1251labeled 280-4A) drops off at very high FgD concentrations, indicating that any FgD bound to the beads nonspecifically through the washing step may bind '251-labeled 280-4A antibody in the subsequent incubation and then be released from the beads and washed away. These complications (particularly nonspecific binding) may interfere with use of the solid-phase RIA in its present form for clinical purposes; however, the principle of this assay, and these reagents, could be adapted to other types of solid-phase technology. Use of large (4.8 to 6.4 mm) polystyrene beads as the solid-phase support may alleviate the nonspecific binding problem in such assays, and enzyme-linked assays with these specific MoAb reagents may increase the sensitivity of detection even further.
